Breaking news on irritable bowel syndrome
(IBS)
$6.75M Awarded To Case Western Reserve To Study IBD published
Thu, 22 Dec 2011 01:00:00 PST
Investigators at Case Western Reserve University School of Medicine received a $6.75 million Program Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study the role of innate immunity in inflammatory bowel disease (IBD)...
Risk Factors For Chronic Cerebrospinal Venous Insufficiency Are Similar To Risk Factors For Developing Multiple Sclerosis: UB Study published
Thu, 01 Dec 2011 02:00:00 PST
Summary: A vascular condition called chronic cerebrospinal venous insufficiency (CCSVI), which has attracted global attention as possibly being correlated with MS has, for the first time, been studied for the presence of risk factors in subjects who do not have a neurological disease...
Probiotics For Gut Health: VSL#3 Has Designations For Specific GI Issues published
Tue, 22 Nov 2011 00:00:00 PST
As clinical studies continue to validate the use of probiotics to help promote general gastrointestinal health, a growing U.S. market1 for probiotics indicates that the U.S. healthcare community and consumers alike are recognizing the value of these beneficial microorganisms...
Targeted Antibiotic Drug Safest Among Recommended Treatments For Irritable Bowel Disease published
Wed, 02 Nov 2011 02:00:00 PST
Among the most commonly used treatments for irritable bowel syndrome which affects as many as 20 percent of the United States population a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials. The study, for presentation at the American College of Gastroenterology annual meeting in Washington, D.C...
Antibiotic-Associated Diarrhea Responds To Probiotics published
Tue, 01 Nov 2011 04:00:00 PST
'Good bugs' look promising as anti-inflammatory agent for patients with ulcerative colitis, psoriasis, chronic fatigue syndrome In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammat...
Stress Associated With Grief, Natural Disasters, And Emotional Abuse Plays Ongoing Role In IBS published
Tue, 01 Nov 2011 03:00:00 PST
The psychological and emotional traumas experienced over a lifetime -- such as the death of a loved one, divorce, natural disaster, house fire or car accident, physical or mental abuse -- may contribute to adult irritable bowel syndrome (IBS), according to the results of a study unveiled at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC...
Research Could Lead To New Treatments For IBD, Viral Infections published
Thu, 20 Oct 2011 02:00:00 PST
The intestinal ecosystem is even more dynamic than previously thought, according to two studies by UT Southwestern Medical Center researchers published in the latest issue of Science...
Negative Emotions Influence Brain Activity During Anticipation And Experience Of Pain published
Wed, 21 Sep 2011 00:00:00 PST
Neuroticism - the tendency to experience negative emotions - significantly affects brain processing during pain, as well as during the anticipation of pain, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association...
Novel Cytokine Protects Mice From Colitis published
Wed, 24 Aug 2011 00:00:00 PST
Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition...
Where's The Beef? Recalled! 60,000 Pounds Off Major Market Shelves published
Mon, 15 Aug 2011 09:00:00 PST
This pesky E. Coli bacteria is getting on the nation's nerves, and in an effort to keep it off our plates, at least three major grocery market chains have recalled some of their ground beef packages because they could be contaminated with bacteria critter. The U.S...
Lexicon Announces Publication Of Results From The Phase 2 Trial Of LX1031 In Patients With Irritable Bowel Syndrome In Journal Of Gastroenterology published
Fri, 12 Aug 2011 01:00:00 PST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology...
Constipated? New Drug Linaclotide May Bring Serious Relief Home published
Thu, 11 Aug 2011 11:00:00 PST
In a new study funded by Ironwood Pharmaceuticals, an experimental drug called linaclotide can help reduce the symptoms of chronic constipation, which may serve as a serious relief for many. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat...
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial published
Sat, 30 Jul 2011 00:00:00 PST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 clinical trial of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d)...
FDA Grants Fast Track Designation To Tioga Pharmaceuticals' Asimadoline For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome published
Thu, 02 Jun 2011 00:00:00 PST
Tioga Pharmaceuticals, Inc. announced that its investigational compound asimadoline has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS)...
That Anxiety May Be In Your Gut, Not In Your Head published
Tue, 17 May 2011 08:00:00 PST
For the first time, researchers at McMaster University have conclusive evidence that bacteria residing in the gut influence brain chemistry and behaviour. The findings are important because several common types of gastrointestinal disease, including irritable bowel syndrome, are frequently associated with anxiety or depression...
Study Suggests Digestive Problems Early In Life May Increase Risk For Depression published
Fri, 13 May 2011 01:00:00 PST
Depression and anxiety may result from short-term digestive irritation early in life, according to a study of laboratory rats by researchers at the Stanford University School of Medicine. The findings suggest that some human psychological conditions may be the result, rather than the cause, of gastrointestinal disorders such as irritable bowel syndrome...
Cedars-Sinai Research Deepens Understanding Of Most Common Gastrointestinal Disorder In U.S., Linking It To Bacterial Overgrowth, Food Poisoning published
Wed, 11 May 2011 01:00:00 PST
Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people. One study provides further evidence that IBS is linked to an overgrowth of bacteria in the gut...
2011 Digestive Disease Week: UNC Research Highlights published
Tue, 10 May 2011 05:00:00 PST
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery...
Scientists Unmask Mysterious Cells As Key 'Border Patrol Agents' In The Intestine published
Tue, 10 May 2011 00:00:00 PST
Researchers at UT Southwestern Medical Center have uncovered new clues about how the intestine maintains friendly relations with the 100 trillion symbiotic bacteria that normally live in the digestive tract...
Ironwood And Forest To Present Linaclotide Results From Phase 3 Trials In Patients With Irritable Bowel Syndrome With Constipation published
Thu, 05 May 2011 05:00:00 PST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation (IBS-C) during the 2011 Digestive Disease Week (DDW) annual meeting that will be held in Chicago from May 7 through May 10, 2011...
C. Difficile Increases Risk Of Death Sixfold In Patients With Inflammatory Bowel Disease published
Wed, 20 Apr 2011 00:00:00 PST
Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness...
Peppermint Earns Respect In Mainstream Medicine published
Tue, 19 Apr 2011 07:00:00 PST
University of Adelaide researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome, which affects up to 20% of the population...
Salix Receives Anticipated FDA Complete Response Letter On XIFAXAN(R) 550 Mg Tablets Non-C IBS Supplemental New Drug Application published
Fri, 11 Mar 2011 02:00:00 PST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on March 7, 2011 for the supplemental New Drug Application (sNDA) for XIFAXANŽ (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating...
Symptoms In Irritable Bowel Syndrome Improved By Exercise published
Thu, 27 Jan 2011 00:00:00 PST
The study, which was conducted at Sahlgrenska University Hospital in Gothenburg and at Alingsas Hospital, included 102 IBS patients between the ages of 18 and 65. Half the group was randomly allocated to increase their physical activity and the other half to maintain their usual lifestyle. Both groups received supportive phone calls from a physiotherapist...
Furiex Receives FDA Fast Track Designation Of MuDelta For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome published
Wed, 26 Jan 2011 01:00:00 PST
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)...
)
|
|
